Ascendis Pharma A/S (NASDAQ:ASND) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Wednesday.

According to Zacks, “Ascendis Pharma A/S is a biopharmaceutical company. The company’s product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. “

A number of other research analysts also recently commented on ASND. TheStreet upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, September 6th. Leerink Swann reiterated a “buy” rating on shares of Ascendis Pharma A/S in a research report on Friday, September 2nd. Finally, Wedbush assumed coverage on Ascendis Pharma A/S in a research report on Monday, September 26th. They set an “outperform” rating and a $34.00 price target for the company.

Ascendis Pharma A/S (NASDAQ:ASND) traded down 5.43% during mid-day trading on Wednesday, reaching $19.00. The company had a trading volume of 1,369,941 shares. The firm’s market capitalization is $478.67 million. The stock’s 50-day moving average is $19.96 and its 200 day moving average is $16.30. Ascendis Pharma A/S has a 12 month low of $11.92 and a 12 month high of $21.79.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings data on Wednesday, August 31st. The company reported ($0.59) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.69) by $0.10. Ascendis Pharma A/S had a negative return on equity of 47.61% and a negative net margin of 818.32%. On average, analysts predict that Ascendis Pharma A/S will post ($3.14) earnings per share for the current fiscal year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S is a clinical-stage biopharmaceutical company. The Company is engaged in applying its TransCon technology to develop a pipeline of long-acting prodrug therapies that address markets with unmet medical needs. The Company is developing its product candidate, TransCon human growth hormone (TransCon hGH) for once-weekly administration to treat growth hormone deficiency (GHD) and other indications.

5 Day Chart for NASDAQ:ASND

Receive News & Stock Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related stocks with our FREE daily email newsletter.